A study demonstrated that in a PD mouse model, oral administration of sodium butyrate increased colonic GLP-1 levels, upregulated GLP-1 receptors (GLP-1R) in the brain, and improved neurobehavioral disorders [48]. Here, GLP1R is linked to Parkinson disease.